featured
Preoperative Durvalumab or Durvalumab Plus Tremelimumab for Resectable HNSCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma
Clin. Cancer Res 2024 Mar 08;[EPub Ahead of Print], CG Kim, MH Hong, D Kim, BH Lee, H Kim, CY Ock, G Kelly, YJ Bang, G Kim, JE Lee, C Kim, SH Kim, HJ Hong, YM Park, NS Sim, H Park, JW Park, CG Lee, KH Kim, G Park, I Jung, D Han, JH Kim, J Cha, I Lee, M Kang, H Song, C Oum, S Kim, S Kim, Y Lim, S Kim-Schulze, M Merad, SO Yoon, HJ Kim, YW Koh, HR KimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.